Ligand Pharmaceuticals Incorporated
LGND
$210.99
$3.191.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.37% | 122.85% | 14.68% | 46.34% | 52.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.37% | 122.85% | 14.68% | 46.34% | 52.35% |
| Cost of Revenue | -40.40% | 205.51% | 14.70% | 520.51% | -47.85% |
| Gross Profit | 46.95% | 107.47% | 14.67% | -143.39% | 86.41% |
| SG&A Expenses | -2.26% | 16.22% | 14.48% | 71.68% | 60.11% |
| Depreciation & Amortization | -1.96% | -1.95% | 0.01% | 0.87% | -0.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.64% | 50.19% | 11.03% | 192.93% | 30.73% |
| Operating Income | 1,087.91% | 393.82% | 31.51% | -1,326.87% | 150.24% |
| Income Before Tax | 244.85% | 2,326.49% | 117.16% | -144.23% | -329.28% |
| Income Tax Expenses | 247.88% | 2,764.83% | 147.30% | -128.30% | -643.54% |
| Earnings from Continuing Operations | 244.06% | 1,735.15% | 109.34% | -149.28% | -270.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 244.06% | 1,735.15% | 109.34% | -149.28% | -270.93% |
| EBIT | 1,087.91% | 393.82% | 31.51% | -1,326.87% | 150.24% |
| EBITDA | 173.94% | 217.08% | 9.67% | -341.22% | 85.57% |
| EPS Basic | 238.56% | 1,638.26% | 108.71% | -145.54% | -257.35% |
| Normalized Basic EPS | 345.19% | 1,045.41% | 38.70% | -1,405.94% | -2,213.87% |
| EPS Diluted | 228.93% | 1,556.41% | 108.33% | -146.57% | -259.09% |
| Normalized Diluted EPS | 328.81% | 997.22% | 34.53% | -1,434.24% | -2,237.82% |
| Average Basic Shares Outstanding | 3.96% | 6.29% | 7.21% | 8.23% | 8.63% |
| Average Diluted Shares Outstanding | 11.41% | 12.00% | 10.53% | 5.90% | 7.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |